Business · 07/05/2003Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for TRACLEER Patent Extension
Summary
The Food and Drug Administration has officially confirmed the regulatory review period for the patent extension of TRACLEER, a human drug product, as required by law after receiving a submission from the Department of Commerce.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →